Jessy Joy van Kleef1, Emil Ter Veer1, Héctor G van den Boorn1, Sandor Schokker1, Lok Lam Ngai1, Mariska J Prins1, Nadia Haj Mohammad2, Lonneke V van de Poll-Franse3,4,5, Aeilko H Zwinderman6, Martijn G H van Oijen1, Mirjam A G Sprangers7, Hanneke W M van Laarhoven1. 1. Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. 2. Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. 3. CoRPS - Center of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, the Netherlands. 4. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands. 5. Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute, Amsterdam, the Netherlands. 6. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, Amsterdam, the Netherlands. 7. Amsterdam Public Health, Amsterdam University Medical Centers, University of Amsterdam, Department of Medical Psychology, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Palliative systemic therapy can prolong life and reduce tumour related symptoms for patients with advanced oesophagogastric cancer. However, side effects of treatment could negatively impact health-related quality of life (HRQoL). Our aim was to review the literature and conduct a meta-analysis to examine the effect of palliative systemic therapy on HRQoL. METHODS: EMBASE, Medline and CENTRAL were searched for phase II/III randomized controlled trials (RCTs) till April 2018 investigating palliative systemic therapy and HRQoL. Meta-analysis was performed on baseline and follow-up summary values of Global Health Status (GHS) and other EORTC scales. A clinically relevant change and difference of 10 points (scale 0-100) was set to assess the course of HRQoL over time within treatment arms as well as between arms. RESULTS: We included 43 RCTs (N = 13,727 patients). In the first-line and beyond first-line treatment setting, pooled baseline GHS mean estimates were 54.6 (51.9-57.3) and 57.9 (55.7-60.1), respectively. Thirty-nine (81.3%) treatment arms showed a stable GHS over the course of time. Anthracycline-based triplets, fluoropyrimidine-based doublets without cisplatin, and the addition of trastuzumab to chemotherapy were found to have favourable HRQoL outcomes. HRQoL benefit was observed for taxane monotherapy and several targeted agents over best supportive care beyond first-line. CONCLUSIONS: Patients reported impaired GHS at baseline and generally remained stable over time. Anthracycline-based triplets and fluoropyrimidine-based doublets without cisplatin may be preferable first-line treatment options regarding HRQoL for HER2-negative disease. Taxanes and targeted agents could provide HRQoL benefit beyond first-line compared to best supportive care.
BACKGROUND: Palliative systemic therapy can prolong life and reduce tumour related symptoms for patients with advanced oesophagogastric cancer. However, side effects of treatment could negatively impact health-related quality of life (HRQoL). Our aim was to review the literature and conduct a meta-analysis to examine the effect of palliative systemic therapy on HRQoL. METHODS: EMBASE, Medline and CENTRAL were searched for phase II/III randomized controlled trials (RCTs) till April 2018 investigating palliative systemic therapy and HRQoL. Meta-analysis was performed on baseline and follow-up summary values of Global Health Status (GHS) and other EORTC scales. A clinically relevant change and difference of 10 points (scale 0-100) was set to assess the course of HRQoL over time within treatment arms as well as between arms. RESULTS: We included 43 RCTs (N = 13,727 patients). In the first-line and beyond first-line treatment setting, pooled baseline GHS mean estimates were 54.6 (51.9-57.3) and 57.9 (55.7-60.1), respectively. Thirty-nine (81.3%) treatment arms showed a stable GHS over the course of time. Anthracycline-based triplets, fluoropyrimidine-based doublets without cisplatin, and the addition of trastuzumab to chemotherapy were found to have favourable HRQoL outcomes. HRQoL benefit was observed for taxane monotherapy and several targeted agents over best supportive care beyond first-line. CONCLUSIONS:Patients reported impaired GHS at baseline and generally remained stable over time. Anthracycline-based triplets and fluoropyrimidine-based doublets without cisplatin may be preferable first-line treatment options regarding HRQoL for HER2-negative disease. Taxanes and targeted agents could provide HRQoL benefit beyond first-line compared to best supportive care.
Authors: Charlotte I Stroes; Sandor Schokker; Mohammed Khurshed; Stephanie O van der Woude; Ron Aa Mathôt; Marije Slingerland; Judith de Vos-Geelen; Massimo Zucchetti; Cristina Matteo; Erik van Dijk; Bauke Ylstra; Victor Thijssen; Sarah Derks; Tesfay Godefa; Willemieke Dijksterhuis; Gerben E Breimer; Otto M van Delden; Rob Ha Verhoeven; Sybren L Meijer; Maarten F Bijlsma; Hanneke Wm van Laarhoven Journal: Ther Adv Med Oncol Date: 2022-06-28 Impact factor: 5.485
Authors: Joost Besseling; Jan Reitsma; Judith A Van Erkelens; Maike H J Schepens; Michiel P C Siroen; Cathelijne M P Ziedses des Plantes; Mark I van Berge Henegouwen; Laurens V Beerepoot; Theo Van Voorthuizen; Lia Van Zuylen; Rob H A Verhoeven; Hanneke van Laarhoven Journal: Cancers (Basel) Date: 2021-01-05 Impact factor: 6.639
Authors: Fleur van der Sijde; Laura Schafthuizen; Freek R van 't Land; Miranda Moskie; Hanneke W M van Laarhoven; Monique van Dijk; Casper H J van Eijck Journal: Support Care Cancer Date: 2021-11-11 Impact factor: 3.603
Authors: M Santero; J Pérez-Bracchiglione; R Acosta-Dighero; A G Meade; A Antequera; A Auladell-Rispau; M J Quintana; C Requeijo; G Rodríguez-Grijalva; K Salas-Gama; R Dorantes-Romandia; J Salazar; I Solà; G Urrútia; X Bonfill Cosp Journal: BMC Cancer Date: 2021-06-16 Impact factor: 4.430
Authors: Willemieke P M Dijksterhuis; Marianne C Kalff; Anna D Wagner; Rob H A Verhoeven; Valery E P P Lemmens; Martijn G H van Oijen; Suzanne S Gisbertz; Mark I van Berge Henegouwen; Hanneke W M van Laarhoven Journal: J Natl Cancer Inst Date: 2021-11-02 Impact factor: 13.506
Authors: Zarah M Bood; Michael Scherer-Rath; Mirjam A G Sprangers; Liesbeth Timmermans; Ellen van Wolde; Sayra M Cristancho; Fenna Heyning; Silvia Russel; Hanneke W M van Laarhoven; Esther Helmich Journal: Cancer Rep (Hoboken) Date: 2021-07-26